MeadowBrook Investment Advisors LLC Invests $30,000 in Intuitive Surgical, Inc. (NASDAQ:ISRG)

MeadowBrook Investment Advisors LLC purchased a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 90 shares of the medical equipment provider’s stock, valued at approximately $30,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Spire Wealth Management acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at about $1,987,000. Clearstead Trust LLC purchased a new position in shares of Intuitive Surgical in the 4th quarter valued at about $583,000. Connecticut Wealth Management LLC raised its stake in shares of Intuitive Surgical by 4.4% during the 4th quarter. Connecticut Wealth Management LLC now owns 1,081 shares of the medical equipment provider’s stock worth $365,000 after buying an additional 46 shares during the period. National Bank of Canada FI lifted its holdings in Intuitive Surgical by 72.2% during the fourth quarter. National Bank of Canada FI now owns 359,965 shares of the medical equipment provider’s stock valued at $119,091,000 after purchasing an additional 150,897 shares in the last quarter. Finally, TCG Advisory Services LLC lifted its stake in Intuitive Surgical by 4,938.9% in the 4th quarter. TCG Advisory Services LLC now owns 66,715 shares of the medical equipment provider’s stock valued at $22,507,000 after buying an additional 65,391 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now owns 25,319 shares in the company, valued at $9,385,753.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intuitive Surgical news, EVP Robert Desantis sold 1,498 shares of the stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $369.92, for a total transaction of $554,140.16. Following the completion of the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the sale, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The disclosure for this sale can be found here. Insiders have sold 228,637 shares of company stock worth $88,483,248 in the last ninety days. 0.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on ISRG. Mizuho raised their target price on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Piper Sandler boosted their price target on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday, April 19th. Raymond James increased their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Robert W. Baird decreased their price target on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a research note on Friday, April 19th. Finally, Truist Financial lifted their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Price Performance

Shares of ISRG traded up $6.23 during mid-day trading on Tuesday, reaching $389.28. The company’s stock had a trading volume of 258,383 shares, compared to its average volume of 1,600,185. The company’s 50 day moving average is $385.29 and its 200 day moving average is $351.11. The stock has a market cap of $138.08 billion, a PE ratio of 69.79, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm’s revenue was up 11.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.00 earnings per share. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.